Why Drug Prices for Some Big Medicines Will Remain High for a Longer Time
Two little-known provisions in the One Big Beautiful Bill Act signed by President Trump in July will delay Medicare price negotiations for some of the biggest-selling drugs in the world, including Merck's Keytruda, which is used to treat cancer and had $17.9 billion in U.S. sales in 2024. Other drugs, such as Johnson & Johnson's Darzalex, will be excluded entirely.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
BD Businesses Become First in MedTech to Achieve HIRC's Diamond Badge Across All Supply Chain Resiliency Categories
FRANKLIN LAKES, N.J., Aug. 5, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that its Urology and Critical Care (UCC) and Surgery business units are the first in the medical technology industry to achieve a diamond-level rating for all seven supply chain resilience domains of the Healthcare Industry Resilience Collaborative's (HIRC) Resiliency Badging program. "Achieving HIRC's Diamond Status Resiliency Badge recognizes BD's commitment to building a resilient end-to-end supply chain across multiple product categories and our relentless pursuit of process excellence and continuous improvement," said Tony Ezell, executive vice president and president of the Americas region for BD. "Hundreds of millions of patients depend on BD, and this recognition is a testament to the work our team does every day to ensure products arrive on time and in the right quantities." HIRC is a non-profit health care supply chain trade association founded in 2019 by a group of health care systems and trading partners focused on increasing transparency and resiliency. The Resiliency Badge Program includes a rigorous audit to assess supply chain resiliency, ensuring alignment with HIRC's standards for supply continuity, risk mitigation and operational efficiency. After completing a comprehensive audit, HIRC recognized BD for differentiated resiliency in all domain areas for its Surgery and UCC businesses, including demand planning, supplier management, inventory management, logistics, supply chain visibility, risk management and continency planning, and operational health. BD was one of the first companies recognized by HIRC after receiving the Transparency Partner Badge in 2023. This diamond-level distinction builds on that recognition and demonstrates BD's ongoing investment in its supply chain and manufacturing operations, including increasing safety stock and capacity to allow greater flexibility for the most critical products and improving order management interfaces so customers have real-time insights into supply and deliveries. About BD BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit or connect with us on LinkedIn at X (formerly Twitter) @BDandCo or Instagram @becton_dickinson. Contacts: Media: Investors: Fallon McLoughlin Adam Reiffe BD Corporate Communications BD Investor Relations 201.258.0361 201.847.6927 View original content to download multimedia: SOURCE BD (Becton, Dickinson and Company) Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
23 minutes ago
- Yahoo
Enanta Pharmaceuticals to Participate in the H.C. Wainwright & Co. "HCW@Home" Series
WATERTOWN, Mass., August 05, 2025--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that members of management will participate in a virtual fireside chat on Tuesday, August 12, 2025 at 1:00 p.m. ET as part of the H.C. Wainwright & Co. "HCW@Home" series. A live webcast of the event will be accessible by visiting the "Events and Presentations" section on the "Investors" page of Enanta's website at or by registering here. A replay of the webcast will be available following the presentation and will be archived for at least 30 days. About Enanta Pharmaceuticals, is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs with an emphasis on indications in virology and immunology. Enanta's clinical programs are currently focused on respiratory syncytial virus (RSV) and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, including KIT and STAT6 inhibition. Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing Hepatitis C virus (HCV) infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta's royalties from HCV products developed under its collaboration with AbbVie contribute ongoing funding to Enanta's operations. Please visit for more information. View source version on Contacts Media and Investors Contact: Jennifer Viera617-744-3848jviera@
Yahoo
23 minutes ago
- Yahoo
Garmin announces collaborations with leading brands for Garmin Marathon Series
Companies will bring exciting activations to the expo, course and finish line festival OLATHE, Kan., Aug. 5, 2025 /PRNewswire/ -- Garmin (NYSE: GRMN) today announced Brooks, Dexcom, Maurten, Shokz and Therabody will support the Garmin Marathon Series with products and programming, beginning with the inaugural races in Toledo, Ohio on Sunday, Sept. 21. "As leaders in their respective fields, these brands are the ideal collaborators to enrich the signature experience we're creating for the Garmin Marathon Series. Each brings something unique to our events, whether they're engaging with runners at the two-day expo, providing support on the course or helping finishers recover and celebrate after the race."– Susan Lyman, Garmin Vice President of Consumer Sales and Marketing BrooksBrooks Running creates market-leading performance running footwear, apparel, sports bras, and accessories distributed worldwide, propelled since 1914 by a never-ending curiosity with how humans move, pushing the limits of motion science, engineering, and technology to create gear that unlocks the power of energy and movement for everyone. Each participant of the Garmin Marathon Series will receive a branded Brooks running shirt to commemorate the event. Additionally, Brooks will be onsite at the expo with its latest gear and along the course at a designated cheer station. DexcomDexcom empowers people to take control of health through innovative glucose biosensing technology. With Dexcom G7 and Stelo by Dexcom, its first over-the-counter glucose biosensor, it is easier than ever to get started with a biosensor that best suits each user's unique needs. Dexcom G7 and Stelo transform how runners track glucose levels and understand their metabolic health. Dexcom will have a presence at the expo and finish line festival, as well as a dedicated cheer zone along the course. MaurtenKnown for revolutionizing sports nutrition with its debut in 2015, Maurten has gained a reputation as the world's leading nutrition brand for endurance athletes. Runners will have access to Maurten gels at designated aid stations, empowering them to stay fueled and perform their best. Maurten will also be onsite at the expo. ShokzAs the pioneer and leader in open-ear listening, Shokz helps runners stay motivated, aware, and connected—without compromising on comfort or sound quality. Throughout the Garmin Marathon Series, Shokz will showcase its innovative headphones at the expo, power runners through the toughest miles with a high-energy cheer station, and join the celebration at the finish line festival. TherabodyBy supercharging performance with science-backed recovery devices, Therabody enables athletes to train harder, perform better and recover faster. Race participants can take advantage of an exclusive offer on Therabody recovery devices to support their training, and benefit from using them throughout race weekend in Therabody recovery zones at the expo, along the course and at the finish line festival. The Garmin Marathon Series is a bold new chapter in road running events, wholly owned and produced by Garmin, a global leader in fitness technology and pioneer of the first running smartwatch. Launching in fall 2025 with events in Toledo, Ohio, and Tucson, Arizona, the Series offers four race distances: a Boston Marathon qualifier full marathon, USATF-certified half marathon, 10K and 5K1. Registration for the Garmin Marathon Series is currently open for all race distances in Toledo and Tucson. For additional information about the cities, races, community engagement opportunities and future locations, please visit Engineered on the inside for life on the outside, Garmin products have revolutionized the aviation, automotive, fitness, marine and outdoor markets. Dedicated to helping people make the most of the time they spend pursuing their passions, Garmin believes every day is an opportunity to innovate and a chance to beat yesterday. Visit the Garmin Newsroom, email our media team, connect with @garmin on social, or follow our blog. 1Tucson courses are pending certification and subject to change. About Garmin International, Inc. Garmin International, Inc. is a subsidiary of Garmin Ltd. (NYSE: GRMN). Garmin Ltd. is incorporated in Switzerland, and its principal subsidiaries are located in the United States, Taiwan and the United Kingdom. Garmin is a registered trademark of Garmin Ltd. or its subsidiaries. All other brands, product names, company names, trademarks and service marks are the properties of their respective owners. All rights reserved. Notice on Forward-Looking Statements:This release includes forward-looking statements regarding Garmin Ltd. and its business. Such statements are based on management's current expectations. The forward-looking events and circumstances discussed in this release may not occur and actual results could differ materially as a result of known and unknown risk factors and uncertainties affecting Garmin, including, but not limited to, the risk factors listed in the Annual Report on Form 10-K for the year ended December 28, 2024, filed by Garmin with the Securities and Exchange Commission (Commission file number 0-31983), and the Quarterly Report on Form 10-Q for the quarter ended June 28, 2025 filed by Garmin with the Securities and Exchange Commission (Commission file number 001-41118). Copies of such Form 10-K and Form 10-Q are available at No forward-looking statement can be guaranteed. Forward-looking statements speak only as of the date on which they are made and Garmin undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. MEDIA CONTACTS:Elliott View original content to download multimedia: SOURCE Garmin International, Inc.
